RT @GMFHx: Alterations in the gut microbiota are observed in patients with IBS concomitant with small intestinal bacterial overgrowth. A ne…
RT @GMFHx: Alterations in the gut microbiota are observed in patients with IBS concomitant with small intestinal bacterial overgrowth. A ne…
Alterations in the gut microbiota are observed in patients with IBS concomitant with small intestinal bacterial overgrowth. A new study shows that rifaximin exhibits a favorable benefit-to-harm ratio when compared with daily therapies for IBS-D https://t.c
Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. https://t.co/Y5PeKMaNY5
Short-course therapy for diarrhea-predominant irritable bowel syndrome: unders... - Chang C et al. - https://t.co/pdwkea2IPb #microbiome
Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut ... - Dove Medical Press https://t.co/7oanMqYZ67 https://t.co/2S1CDcWWzp